Late differentiation syndrome in acute promyelocytic leukemia: a challenging diagnosis

Detalhes bibliográficos
Autor(a) principal: Cabral, R.
Data de Publicação: 2014
Outros Autores: Caballero, J., Alonso, S., Dávila, J., Cabrero, M., Caballero, D., Vázquez, L., Sánchez-Guijo, F., López, L., Cañizo, M., Mateos, M., González, M.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.16/1856
Resumo: Detailed knowledge about differentiation syndrome (DS) has remained limited. There are 2 large studies conducted by the Spanish workgroup PETHEMA (Programa Español de Tratamientos en Hematología; Spanish Program on Hematology Treatments) and the European group trial (LPA 96-99 and APL 93) in which the incidence, characteristics, prognostic factors and outcome of patients developing DS are evaluated. Both have described the median time of DS development between 10 and 12 days. The severity of the DS has been evaluated in the study conducted by PETHEMA, and severe DS usually occurs at the beginning of the treatment (median of 6 days), as compared with moderate DS (median of 15 days). We report here in two cases of late severe DS, with late diagnosis due to both time and form of presentation. We discuss the physiopathology, clinical presentation, prophylaxis and treatment of DS.
id RCAP_8d8c21a370a5dfa437881da0d22d3958
oai_identifier_str oai:repositorio.chporto.pt:10400.16/1856
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str
spelling Late differentiation syndrome in acute promyelocytic leukemia: a challenging diagnosisdifferentiation syndromeacute promyelocytic leukemiaall trans retinoic acidDetailed knowledge about differentiation syndrome (DS) has remained limited. There are 2 large studies conducted by the Spanish workgroup PETHEMA (Programa Español de Tratamientos en Hematología; Spanish Program on Hematology Treatments) and the European group trial (LPA 96-99 and APL 93) in which the incidence, characteristics, prognostic factors and outcome of patients developing DS are evaluated. Both have described the median time of DS development between 10 and 12 days. The severity of the DS has been evaluated in the study conducted by PETHEMA, and severe DS usually occurs at the beginning of the treatment (median of 6 days), as compared with moderate DS (median of 15 days). We report here in two cases of late severe DS, with late diagnosis due to both time and form of presentation. We discuss the physiopathology, clinical presentation, prophylaxis and treatment of DS.PagePressRepositório Científico do Centro Hospitalar do PortoCabral, R.Caballero, J.Alonso, S.Dávila, J.Cabrero, M.Caballero, D.Vázquez, L.Sánchez-Guijo, F.López, L.Cañizo, M.Mateos, M.González, M.2015-10-06T13:20:41Z2014-11-19T00:00:00Z2014-11-19T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.16/1856engHematol Rep. 2014 Nov 19;6(4):56542038-832210.4081/hr.2014.5654info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2022-09-05T12:40:24ZPortal AgregadorONG
dc.title.none.fl_str_mv Late differentiation syndrome in acute promyelocytic leukemia: a challenging diagnosis
title Late differentiation syndrome in acute promyelocytic leukemia: a challenging diagnosis
spellingShingle Late differentiation syndrome in acute promyelocytic leukemia: a challenging diagnosis
Cabral, R.
differentiation syndrome
acute promyelocytic leukemia
all trans retinoic acid
title_short Late differentiation syndrome in acute promyelocytic leukemia: a challenging diagnosis
title_full Late differentiation syndrome in acute promyelocytic leukemia: a challenging diagnosis
title_fullStr Late differentiation syndrome in acute promyelocytic leukemia: a challenging diagnosis
title_full_unstemmed Late differentiation syndrome in acute promyelocytic leukemia: a challenging diagnosis
title_sort Late differentiation syndrome in acute promyelocytic leukemia: a challenging diagnosis
author Cabral, R.
author_facet Cabral, R.
Caballero, J.
Alonso, S.
Dávila, J.
Cabrero, M.
Caballero, D.
Vázquez, L.
Sánchez-Guijo, F.
López, L.
Cañizo, M.
Mateos, M.
González, M.
author_role author
author2 Caballero, J.
Alonso, S.
Dávila, J.
Cabrero, M.
Caballero, D.
Vázquez, L.
Sánchez-Guijo, F.
López, L.
Cañizo, M.
Mateos, M.
González, M.
author2_role author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Repositório Científico do Centro Hospitalar do Porto
dc.contributor.author.fl_str_mv Cabral, R.
Caballero, J.
Alonso, S.
Dávila, J.
Cabrero, M.
Caballero, D.
Vázquez, L.
Sánchez-Guijo, F.
López, L.
Cañizo, M.
Mateos, M.
González, M.
dc.subject.por.fl_str_mv differentiation syndrome
acute promyelocytic leukemia
all trans retinoic acid
topic differentiation syndrome
acute promyelocytic leukemia
all trans retinoic acid
description Detailed knowledge about differentiation syndrome (DS) has remained limited. There are 2 large studies conducted by the Spanish workgroup PETHEMA (Programa Español de Tratamientos en Hematología; Spanish Program on Hematology Treatments) and the European group trial (LPA 96-99 and APL 93) in which the incidence, characteristics, prognostic factors and outcome of patients developing DS are evaluated. Both have described the median time of DS development between 10 and 12 days. The severity of the DS has been evaluated in the study conducted by PETHEMA, and severe DS usually occurs at the beginning of the treatment (median of 6 days), as compared with moderate DS (median of 15 days). We report here in two cases of late severe DS, with late diagnosis due to both time and form of presentation. We discuss the physiopathology, clinical presentation, prophylaxis and treatment of DS.
publishDate 2014
dc.date.none.fl_str_mv 2014-11-19T00:00:00Z
2014-11-19T00:00:00Z
2015-10-06T13:20:41Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.16/1856
url http://hdl.handle.net/10400.16/1856
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Hematol Rep. 2014 Nov 19;6(4):5654
2038-8322
10.4081/hr.2014.5654
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv PagePress
publisher.none.fl_str_mv PagePress
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1777301180566732800